Rare ashy dermatosis-like hyperpigmentation associated with osimertinib.

Abstract excerpt

Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is the most reliable EGFR-TKI and is widely used as the first-line treatment for EGFR mutation-positive non-small cell lung cancer. Pigmentary changes caused by EGFR-TKIs are unusual, and to the best of my knowledge, hyperpigmentation with osimertinib has rarely been reported as a skin-related adverse event....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acrylamides
• Share to Aniline Compounds
• Share to Carcinoma, Non-Small-Cell Lung